{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:54:11Z","timestamp":1785729251575,"version":"3.56.0"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment of tuberculosis (TB) in solid organ transplant (SOT) recipients is challenging owing to interactions between rifampin and immunosuppressive drugs. Rifabutin, a rifamycin with excellent activity against <jats:italic>Mycobacterium tuberculosis<\/jats:italic> and that induces cytochrome p450 less, may facilitate treatment. We report our experience with rifabutin for treating TB in SOT recipients and review the available literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective observational study of all SOT recipients with TB between January 2000 and December 2019. The clinical characteristics and outcomes of patients treated with and without rifabutin\u2010containing regimens were compared and a literature review was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 31 SOT recipients with TB, among whom 22 (71%) were men and the median age was 62\u00a0years (interquartile range 50\u201020). There were no significant differences between patients treated with rifabutin (n\u00a0=\u00a012), rifampin (n\u00a0=\u00a014), and non\u2010rifamycins (n\u00a0=\u00a05) in clinical cure rates (83.3%, 64.3%, and 100%, respectively; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.21), side effects (25%, 37.5%, and 20%, respectively; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.74), or mortality (16.7%, 35.7%, and 0%, respectively; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.21). Only one patient, treated with rifampin, suffered graft rejection. The literature review identified 59 SOT recipients with TB treated with rifabutin\u2010containing regimens from 8 publications. Overall, the clinical cure, graft rejection, and mortality rates were 93.2%, 5.1%, and 6.8%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rifabutin\u2010containing regimens offer a reliable alternative to rifampin when treating TB in SOT recipients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.13471","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T09:36:26Z","timestamp":1600767386000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rifabutin for treating tuberculosis in solid organ transplant recipients: A retrospective observational study and literature review"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-9269","authenticated-orcid":false,"given":"A.","family":"Gomila\u2010Grange","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Tuberculosis Unit Bellvitge University Hospital\u2010Bellvitge Institute of Biomedical Research (IDIBELL) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"P\u00e9rez\u2010Recio","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tuberculosis Unit Bellvitge University Hospital\u2010Bellvitge Institute of Biomedical Research (IDIBELL) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Camprub\u00ed\u2010Ferrer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tuberculosis Unit Bellvitge University Hospital\u2010Bellvitge Institute of Biomedical Research (IDIBELL) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Llad\u00f3","sequence":"additional","affiliation":[{"name":"Liver Transplantation Unit Bellvitge University Hospital Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fava","sequence":"additional","affiliation":[{"name":"Kidney Transplantation Unit Bellvitge University Hospital Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garc\u00eda\u2010Romero","sequence":"additional","affiliation":[{"name":"Cardiac Transplantation Unit Bellvitge University Hospital Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Grijota\u2010Camino","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tuberculosis Unit Bellvitge University Hospital\u2010Bellvitge Institute of Biomedical Research (IDIBELL) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sab\u00e9","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tuberculosis Unit Bellvitge University Hospital\u2010Bellvitge Institute of Biomedical Research (IDIBELL) Barcelona Spain"},{"name":"Department of Clinical Sciences University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Tuberculosis Unit Bellvitge University Hospital\u2010Bellvitge Institute of Biomedical Research (IDIBELL) Barcelona Spain"},{"name":"Department of Clinical Sciences University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/427692"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit488"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12100"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13259"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001224"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.09.060"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0068"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw024"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.148710"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(02)01189-0"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.911034"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12943"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.01.075"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)00947-3"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2012.01561.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.29.4.532"},{"issue":"4","key":"e_1_2_6_19_1","first-page":"CD005159","article-title":"Rifabutin for treating pulmonary tuberculosis","volume":"2007","author":"Davies GR","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199705150-00015"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1704255"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002014"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13513"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2018.05.002"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.13471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T05:12:55Z","timestamp":1693545175000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.13471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/tid.13471"],"URL":"https:\/\/doi.org\/10.1111\/tid.13471","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"2020-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13471"}}